English Summary
Changzhou Institute of Materia Medica Co., Ltd. is a China Little Giant company report summary for overseas readers. The company is associated with Jiangsu. The report is indexed under Biomedicine and medical devices. The Chinese report was published on 2026-06-14. The summary covers company profile, product direction, industry-chain role, technology, patent/R&D signals, scale indicators and policy-material checkpoints.
Report Snapshot
| Company | Changzhou Institute of Materia Medica Co., Ltd. |
| Region | Jiangsu |
| Industry | Biomedicine and medical devices |
| Published | 2026-06-14 |
| Chinese report | Open |
Company and Recognition Snapshot
Changzhou Institute of Materia Medica Co., Ltd. is indexed as a national-level Little Giant enterprise in Jiangsu. The English profile places the company under Biomedicine and medical devices and records 2024 6th batch as the available recognition context.
| Recognition batch | 2024 6th batch |
| Region | Jiangsu |
| Industry | Biomedicine and medical devices |
| Registered capital | RMB 56.08 million |
| Employee signal | 223 employees |
| Listed status | Not listed |
| Patent signal | 96 patent-related records |
| R&D signal | R&D investment detail not published in the English dataset |
Business and Industry-chain Position
Chinese public records indicate R&D, design and engineering activity. The recorded industry-chain position is Biomedicine and medical devices / Recorded position. This places the company in a policy-relevant segment for peer comparison by region, industry and batch.
Technology, Patent and R&D Signals
The public profile records 96 patent-related records. The R&D signal is: R&D investment detail not published in the English dataset. Patent and R&D information should be read with product direction, customer evidence and chain position rather than as isolated threshold items.
Policy-material Review Points
- Verify whether the company's main business, niche market and product evidence all point to Biomedicine and medical devices.
- Check that patent, R&D, employee and financial fields support the same core product direction.
- Compare the company with peers in the same province, industry and recognition batch before using the profile for supplier screening or policy research.
- Use the linked Chinese source report for original-language evidence and source links.
Original Report and Profile
For the underlying database record, open the English company profile. For full-length analysis, original-language wording and public evidence links, open the Chinese source report.